Wang Ya-Feng, Wang Xiao-Yan, Ren Zhe, Qian Chui-Wen, Li Yi-Cheng, Kaio Kitazato, Wang Qing-Duan, Zhang Yan, Zheng Li-Yun, Jiang Jin-Hua, Yang Chong-Ren, Liu Qing, Zhang Ying-Jun, Wang Yi-Fei
Institute of Pharmacology Science, Jinan University Guangdong, Guangzhou, China.
Antiviral Res. 2009 Nov;84(2):150-8. doi: 10.1016/j.antiviral.2009.08.004. Epub 2009 Aug 20.
Coxsackie virus B3 (CVB3) is believed to be a major contributor to viral myocarditis since virus-associated apoptosis plays a role in the pathogenesis of experimental myocarditis. In this study, we investigated the in vitro and in vivo antiviral activities of Phyllaemblicin B, the main ellagitannin compound isolated from Phyllanthus emblica, a Chinese herb medicine, against CVB3. Herein we report that Phyllaemblicin B inhibited CVB3-mediated cytopathic effects on HeLa cells with an IC(50) value of 7.75+/-0.15microg/mL. In an in vivo assay, treatment with 12mgkg(-1)d(-1) Phyllaemblicin B reduced cardiac CVB3 titers, decreased the activities of LDH and CK in murine serum, and alleviated pathological damages of cardiac muscle in myocarditic mice. Moreover, Phyllaemblicin B clearly inhibited CVB3-associated apoptosis effects both in vitro and in vivo. These results show that Phyllaemblicin B exerts significant antiviral activities against CVB3. Therefore, Phyllaemblicin B may represent a potential therapeutic agent for viral myocarditis.
柯萨奇病毒B3（CVB3）被认为是病毒性心肌炎的主要致病因素，因为病毒相关的细胞凋亡在实验性心肌炎的发病机制中起作用。在本研究中，我们研究了从中药余甘子中分离出的主要鞣花单宁化合物余甘子素B对CVB3的体外和体内抗病毒活性。在此我们报告，余甘子素B抑制CVB3介导的对HeLa细胞的细胞病变效应，IC（50）值为7.75±0.15μg/mL。在体内试验中，用12mgkg（-1）d（-1）的余甘子素B治疗可降低心脏CVB3滴度，降低小鼠血清中LDH和CK的活性，并减轻心肌炎小鼠心肌的病理损伤。此外，余甘子素B在体外和体内均明显抑制CVB3相关的凋亡效应。这些结果表明，余甘子素B对CVB3具有显著的抗病毒活性。因此，余甘子素B可能是一种潜在的病毒性心肌炎治疗药物。
